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Abstract	
	 	
The	Myc	proteins	comprise	a	family	of	ubiquitous	regulators	of	gene	expression	implicated	
in	over	half	of	all	human	cancers.		They	interact	with	a	large	number	of	other	proteins,	such	
as	transcription	factors,	chromatin-modifying	enzymes	and	kinases.	Remarkably	few	of	these	
interactions	 have	 been	 characterized	 structurally.	 This	 is	 at	 least	 in	 part	 due	 to	 the	
intrinsically	disordered	nature	of	Myc	proteins,	which	adopt	a	defined	conformation	only	in	
the	 presence	 of	 binding	 partners.	 Due	 to	 this	 behaviour,	 crystallographic	 studies	 on	Myc	
proteins	 have	 been	 limited	 to	 short	 fragments	 in	 complex	 with	 other	 proteins.	 Most	
recently,	 we	 determined	 the	 crystal	 structure	 of	 Aurora-A	 kinase	 domain	 bound	 to	 a	 28	
amino	acid	fragment	of	the	N-Myc	transactivation	domain.	The	structure	reveals	an	α-helical	
segment	 within	 N-Myc	 capped	 by	 two	 tryptophan	 residues	 that	 recognize	 the	 surface	 of	
Aurora-A.	 The	 kinase	 domain	 acts	 as	 a	 molecular	 scaffold,	 independently	 of	 its	 catalytic	
activity,	upon	which	this	region	of	N-Myc	becomes	ordered.	The	binding	site	for	N-Myc	on	
Aurora-A	is	disrupted	by	certain	ATP-competitive	inhibitors,	such	as	MLN8237	(alisertib)	and	
CD532	 and	 explains	 how	 these	 kinase	 inhibitors	 are	 able	 to	 disrupt	 the	 protein-protein	
interaction	to	effect	Myc	destabilization.	Structural	studies	on	this	and	other	Myc	complexes	
will	 lead	to	the	design	of	protein-protein	 interaction	 inhibitors	as	chemical	 tools	 to	dissect	
the	complex	pathways	of	Myc	 regulation	and	 function,	which	may	be	developed	 into	Myc	
inhibitors	for	the	treatment	of	cancer.	
	
	
Introduction	
	
Myc	 proteins	 are	 transcription	 factors	 that	 markedly	 alter	 gene	 expression	 through	 both	
activation	and	repression	[1-3].	The	three	Myc	protein	family	members	in	humans	(c-Myc,	N-
Myc,	 L-Myc)	 are	 all	 aberrantly	 expressed	 in	 cancers.	 Myc	 overexpression	 dramatically	
changes	the	landscape	of	gene	expression,	altering	many	of	the	cellular	properties	that	are	
hallmarks	of	 cancer	e.g.	 resistance	 to	 cell	 death,	 sustained	proliferation	and	promotion	of	
angiogenesis	 [4].	Inhibition	of	Myc	is	a	validated	therapeutic	strategy,	but	the	development	
of	clinical	compounds	that	target	intrinsically	disordered	proteins	(IDPs)	such	as	Myc	directly	
is	a	daunting	challenge	due	to	the	absence	of	stable	and	well-defined	pockets	that	could	be	
probed	with	small	molecules	[5,6].	Because	of	these	difficulties,	many	attempts	have	been	
made	to	inhibit	Myc	indirectly,	through	inhibition	of	targets	that	act	downstream	of	Myc	in	
various	Myc-driven	 cellular	 processes	 [7]	 or	 upstream	 of	Myc,	 such	 as	 inhibition	 of	 BRD4	
recruitment	 to	 chromatin	 using	 BET	 bromodomain	 inhibitors,	 which	 is	 effective	 in	 many	
Myc-driven	cancers	because	BRD4	is	often	required	to	drive	transcription	of	MYC	 itself	[8].	
Here	we	 review	 the	opportunities	 for	 targeting	 the	Myc	proteins	 and	 complexes	 in	which	
small	 regions	 of	 Myc	 become	 ordered	 through	 binding	 to	 partner	 proteins.	 Finally,	 we	
discuss	 a	 recently	 postulated	 strategy	 for	 targeting	 the	 stability	 of	Myc	 through	 one	 such	
binding	partner,	Aurora-A.		
	
	
Structural	basis	of	Myc	interactions	
	
While	Myc	polypeptides	alone	are	intrinsically	disordered,	and	are	likely	to	exist	in	multiple	
conformation	states	simultaneously,	there	are	transient	secondary	structure	elements	that,	
in	some	cases,	become	conformationally	stable	while	in	complex	with	a	binding	partner	 [9].	
In	contrast	to	the	emergent	methods	that	might	be	used	to	develop	small	molecule	ligands	
that	recognise	disordered	polypeptides,	 the	ordered	regions	glimpsed	 in	structures	of	Myc	
complexes	 could	be	 targeted	using	established	 structure-based	drug	discovery	approaches	
that	 promise	 greater	 target	 specificity.	 However,	 there	 are	 currently	 only	 four	 crystal	
structures	 of	 Myc	 complexes:	 Importin-a	 [10],	 Max	 [11],	 WDR5	 [12]	 and	 Aurora-A	 [13]	
(Figure	1).	 In	many	of	these	structures,	the	Myc	fragment	forms	a	short,	extended	peptide	
sequence	 and	 only	 in	 the	 complexes	 with	 Aurora-A	 and	 Max	 does	 Myc	 form	 intrachain	
hydrogen	bonds.	c-Myc,	N-Myc	and	L-Myc	have	regions	of	sequence	homology	that	mediate	
interactions	 with	 critical	 partner	 proteins	 (Figure	 1)	 [14].	 The	 most	 C-terminal	 of	 these	
regions	forms	an	essential	DNA-binding	domain	through	formation	of	a	basic	helix-loop-helix	
leucine	zipper	(bHLHZ)	domain	in	complex	with	Max	 [10].	Other	conserved	sequence	motifs	
called	Myc	boxes	(MB0-IV,)	serve	as	docking	sites	for	protein-protein	interactions.	The	Myc	
transactivation	domain	(TAD),	spans	the	N-terminal	conserved	motifs	MB0,	MBI	and	MBII.		
	
	
	
Figure	 1.	 Overview	 of	 Myc	 structures.	 From	 the	 top:	 domain	 structure	 of	 Myc	 proteins	
showing	conserved	regions	as	red	boxes;	MB,	Myc	box;	bHLHZ,	basic	helix-loop-helix	leucine	
zipper;	 functional	 annotation	 of	 regions	 and	 the	 proteins	 that	 interact	 at	 these	 sites;		
structures	of	protein	complexes	containing	Myc	(red).	The	PDB	entries	are,	from	left	to	right,	
1MV0,	5G1X,	4Y7R,	1EE4,	1NKP).	
	
	
The	crystal	structure	of	the	bHLHZ	Myc-Max	complex	bound	to	double-stranded	DNA	shows	
that	an	extensive,	mainly	hydrophobic,	buried	interface	is	formed	between	the	Myc	and	Max	
leucine-zipper	 regions	with	 register	 and	 heterodimer	 specificity	 apparently	maintained	 by	
two	pairs	of	polar	residues	(Arg423/Arg424	of	Myc	and	Gln91/Asn92	of	Max)	which	form	a	
small	 interfacial	 hydrogen	 bond	 network	 [10].	 The	 bHLHZ	 region	 of	 the	 Myc-Max	
heterodimer	 interacts	 directly	 with	 the	 major	 groove	 of	 DNA	 most	 frequently	 in	 gene	
promoter	 regions	 containing	E-boxes	of	 sequence	 ‘CACGTG’.	Myc	and	Max	each	 recognise	
half	 of	 the	 palindromic	 sequence	 through	 a	 set	 of	 similar,	 sequence-specific	 protein-DNA	
interactions	[10].	Nuclear	magnetic	resonance	(NMR)	assignments	are	also	available	for	the	
bHLHZ	domains	of	c-Myc	and	v-Myc	 [15-18].	Co-solution	structures	have	been	determined	
of	the	c-Myc	leucine	zipper	and	a	full	bHLHZ	Myc-Max	complex	in	the	absence	of	DNA	[17,	
18]	which	both	resemble	the	co-crystal	structure	of	the	DNA-bound	Myc-Max	complex	[10].	
Inhibition	of	the	Myc-Max	interaction	has	been	achieved	using	a	version	of	the	Myc	bHLHZ	
domain	containing	 four	mutations	within	the	 leucine	zipper	that	allow	 it	 to	 form	relatively	
inactive	dimers	with	both	Myc	and	Max	 [19,	20].	 The	 recruitment	of	Myc-Max	 to	 sites	on	
chromatin	 depends	 on	other	 chromatin-associated	 factors	 such	 as	 the	b-propeller	 protein	
WDR5,	which	binds	Myc	through	a	highly	conserved	acidic/hydrophobic	sequence	within	the	
MBIIIb	motif	 [12].	The	complementary	basic/hydrophobic	binding	groove	lies	on	one	face	of	
the	WDR5	b-propeller	and	also	mediates	interactions	with	RBBP5	and	KANSL2	via	sequence	
motifs	 similar	 to	 the	 one	 found	 in	MBIIIb.	 Since	WDR5	 also	 recognises,	 via	 other	 binding	
sites,	 various	histone	modifications	 that	 are	 characteristic	of	 active	 chromatin	 it	 is	 able	 to	
influence	the	selection	of	Myc	target	genes	through	recruitment	to	sites	rich	in	such	marks.			
	
NMR	 spectroscopy	 is	 well-suited	 to	 study	 the	 interactions	 of	 intrinsically-disordered	
proteins.	 For	 example,	 backbone	 resonance	 assignment	 has	 been	 performed	 for	 the	 full	
length	murine	B-Myc	[21],	a	rodent	Myc	homologue	which	contains	only	the	TAD	but	shares	
approximately	65%	amino	acid	identity	with	the	c-Myc	TAD.	Using	this	data,	interactions	of	
Prefoldin	subunit	5	 (PFDN5)	and	TATA-binding	protein	were	demonstrated	with	sequences	
within	and	 flanking	B-Myc	MBI	and	MBII.	NMR	has	also	been	used	 to	 investigate	how	 the	
interaction	between	c-Myc	and	Peptidyl-prolyl	cis-trans	isomerase	NIMA-interacting	1	(PIN1)	
is	regulated	by	Cdk1	phosphorylation	[9].	c-Myc	interacts	with	PIN1	via	MB0	in	the	absence	
of	phosphorylation	while	 interaction	via	MB1	 requires	phosphorylation	at	 Ser62.	Chemical	
shift	perturbations	were	also	used	to	map	the	binding	site	of	c-Myc	on	PIN1:	chemical	shifts	
induced	by	binding	of	unphosphorylated	c-Myc	were	restricted	to	a	cleft	between	the	WW	
and	PPIase	domains	while	binding	of	c-Myc	phosphorylated	at	Ser62	affected	a	much	larger	
proportion	 of	 resonances	 spread	 throughout	 the	 entire	 protein	 leading	 the	 authors	 to	
propose	 that	 c-Myc	 and	 PIN1	 form	 a	 fuzzy	multivalent	 complex	which	 is	 anchored	 by	 the	
primary	 point	 of	 contact	 between	 c-Myc	 MB0	 and	 the	 interdomain	 cleft	 of	 PIN1	 [9].	 A	
solution	 structure	 was	 determined	 of	 residues	 55-66	 of	 c-Myc	 in	 complex	 with	 the	 C-
terminal	 SH3	 domain	 of	 BIN1.	 In	 this	 structure,	 Ser62	 of	 c-Myc	 is	 positioned	 close	 to	 an	
acidic	 patch	 on	 the	 binding	 pocket	 surface	 suggesting	 a	 mechanism	 by	 which	
phosphorylation	of	 this	 site	negatively	 regulates	 this	 interaction	 [22].	More	 recently,	 BIN1	
was	observed	to	interact	with	with	several	other	sites	in	the	TAD	suggesting	that	this	may	be	
another	example	of	a	Myc	forming	a	multivalent	complex	[23].	
	
Myc	interacts	with	many	other	binding	partners,	a	summary	of	which	has	been	provided	in	a	
recent,	 comprehensive	 review	 [14].	 These	 binding	 partners	 are	 involved	 in	 transcriptional	
activation	 (e.g.	 histone	 acetyltransferases,	 P-TEFb),	 transcriptional	 repression	 (e.g.	 Miz-1)	
and	 the	 regulation	of	Myc	 protein	 turnover.	 The	development	of	 inhibitors	 that	 block	 the	
interaction	 of	Myc	 with	 chromatin,	 and	 its	 subsequent	 recruitment	 of	 the	 transcriptional	
regulatory	apparatus,	is	a	major	avenue	of	current	investigation	[12,	19,	20].		
	
	
Targeting	Myc	as	an	IDP	
	
Both	 the	 N-terminal	 regulatory	 region	 and	 the	 C-terminal	 bHLHZ	 domain	 of	 Myc	 are	
intrinsically	disordered	in	the	absence	of	binding	partners,	as	reported	by	circular	dichroism	
(CD)	and	NMR	spectroscopies	 [9],	but	as	described	above,	regions	of	 the	protein	do	adopt	
ordered	conformations	upon	binding	to	interaction	partners.	In	contrast	to	the	spontaneous	
transition	of	a	globular	protein	to	its	folded	state	driven	by	the	physicochemical	properties	
of	the	polypeptide,	an	IDP	merely	carries	the	potential	to	adopt	a	particular	conformation,	
or	 samples	 that	 conformation	 among	 a	 diverse	 conformational	 ensemble,	 but	 requires	 its	
binding	partner	 to	act	 as	 a	 template	 for	 folding	and	 stabilisation	of	 a	 single	ordered	 state	
[24].	The	transition	of	a	region	of	the	c-Myb	TAD	to	an	α-helical	conformation	upon	binding	
to	the	CREB-binding	protein	was	investigated	as	an	example	of	“templated	folding”	mode	of	
IDP	 interaction	 [24].	 However,	 as	 mentioned	 above,	 Myc	 may	 interact	 with	 some	 of	 its	
binding	 partners	 transiently	 across	 multiple	 binding	 sites:	 in	 this	 multivalent	 mode	 of	
binding,	which	is	reportedly	common	among	IDPs,	at	any	moment	across	the	population	of	
the	 IDP	molecule,	 each	 individual	 binding	motif	 may	 be	 partly	 bound/ordered	 and	 partly	
unbound/disordered	[9,	23,	25].	
	
Small-molecule	 inhibitors	 that	 bind	 to	 IDPs	 and	 disfavour	 their	 transition	 to	 an	 ordered	
conformation	 competent	 to	 form	a	 stable	 interaction	 are	 an	 emergent	 concept	 and	 there	
are	no	drugs	in	clinical	use	that	are	known	to	work	in	this	way.	However,	targeting	the	c-Myc	
bHLHZ	domain	by	these	means	has	seen	some	early	success.	Myc	bHLHZ	and	Max	form	their	
ordered	 DNA-binding	 structure	 only	 upon	 dimerisation	 and	 as	 monomers	 they	 are	 both	
disordered.	Many	groups	who	have	screened	compound	libraries	for	small	molecules	able	to	
inhibit	the	Myc-Max	interaction	have	discovered	compounds	that	recognise	and	stabilise	the	
disordered	 monomeric	 forms	 of	 Myc	 and	 Max,	 disfavouring	 formation	 of	 the	 ordered	
heterodimer	 [26].	 Ligands	 such	 as	 the	 benzylidene	 rhodanine	 compound	 10058-F4	 were	
shown	to	bind	to	multiple	sites	within	the	c-Myc	bHLHZ	domain	causing	dissociation	of	Myc-
Max	complexes	and	transition	from	an	α-helical	to	a	disordered	state	as	observed	by	CD	and	
NMR	spectroscopies	[27-29].	Molecular	dynamics	simulations	of	10058-F4	interactions	with	
c-Myc	bHLHZ	domain	peptides	suggested	that	the	compound	binds	weakly	to	a	wide	range	
of	 peptide	 conformational	 states	 through	 hydrophobic	 interactions	 but	with	 no	 dominant	
binding	mode	[30].	It	has	been	suggested	that	the	enhanced	conformational	freedom	of	the	
c-Myc	 polypeptide	 in	 the	 presence	 of	 the	 compound	 results	 from	 inhibition	 of	
intramolecular	 interactions	 and	 that	 this	 increases	 the	 affinity	 of	 the	 compound	 for	 the	
protein,	 and	 energetically	 favours	 its	 disordered	 state,	 through	 increased	 entropic	
contributions	 to	 the	 system	 [31].	 While	 target	 specificity	 is	 a	 concern	 with	 this	 mode	 of	
action	and	with	the	rhodanine	scaffold	[32],	some	selectivity	for	Myc-Max	dimers	over	other	
transcription	 factors	was	 demonstrated	 for	 10058-F4	 [27]	 and	optimisation	of	 IDP-binding	
compounds	for	Myc-Max	selectivity	has	been	reported	[26,	33].	
	
	
The	regulation	of	Myc	stability	
	
Myc	 proteins	 are	 turned	 over	 rapidly,	 with	 a	 short	 half-life	 of	 ~20	 minutes	 in	 non-
transformed	 cells	 and	many	 cancer	 cells	 [34].	 Since	 they	 are	 powerful	 oncoproteins,	 tight	
post-translational	control	of	Myc	protein	 levels	 is	clearly	crucial.	Furthermore,	recent	work	
has	 suggested	 that	 the	 turnover	 of	 Myc	 protein	 is	 a	 necessary	 stage	 in	 Myc-driven	
transcription	 [35].	The	degradation	of	Myc	is	mediated	by	the	ubiquitin-proteasome	system,	
a	multi-protein	 cascade	 that	 conjugates	 ubiquitin	 through	 Lys48-linked	 chains	 attached	 to	
Lys	residues	on	substrate	proteins	 [36,	37].	Myc	proteins	are	modified	by	several	different	
E2/E3	pairs,	whose	activities	are	antagonized	by	deubiquitylating	enzymes	(DUBs)	[38,	39].		
	
One	of	the	critical	pathways	that	governs	Myc	stability	involves	the	E3	SCF
Fbxw7
	and	E2	cdc34	
acting	on	a	phosphorylated	form	of	Myc	that	 is	generated	as	a	consequence	of	a	series	of	
post-translational	modifications	[39].	Myc	is	first	phosphorylated	on	Ser62	by	Cdk1/cyclin	B,	
which	 together	with	 proline	 isomerization	 catalyzed	 by	 Pin1,	 increases	 the	 transcriptional	
activity	of	Myc.	Phosphorylation	of	Ser62	also	primes	Myc	for	phosphorylation	at	Thr58	by	
Gsk3b.	 A	 combination	 of	 a	 second	 Pin1-mediated	 proline	 isomerization	 event,	 and	
dephosphorylation	 of	 Ser62	 by	 PP2A,	 generates	 an	 unstable	 form	 of	Myc	 having	 a	 single	
phosphorylation	within	MB1	on	Thr58.	This	forms	a	phosphodegron	motif,	recognized	by	the	
FbxW7	subunit	of	the	E3	ubiquitin	ligase	SCF
Fbxw7
	which,	together	with	cdc34,	modifies	Myc	
with	Lys48-linked	polyubiquitin	chains	that	target	it	for	destruction	by	the	proteasome.	This	
pathway	 has	 been	 the	 subject	 of	 efforts	 to	 target	Myc	 therapeutically,	 using	 inhibitors	 of	
PI3K/Akt/mTOR	that	are	upstream	of	Gsk3b	[6].			
	
Another	target	in	this	pathway	is	the	Ser/Thr	protein	kinase	Aurora-A,	inhibitors	of	which	are	
currently	under	clinical	investigation	in	neuroblastoma	 [40].		Aurora-A	blocks	the	proteolytic	
degradation	 of	 N-Myc	 in	 neuroblastoma	 cells	 through	 binding	 to	 the	 N-Myc/SCF
Fbxw7
	
complex,	and	by	reducing	the	proportion	of	Lys48	linkages	in	the	poly-ubiquitin	chains	[41].	
Intriguingly,	 kinase-dead	mutants	 of	 Aurora-A	 are	 also	 able	 to	 stabilize	N-Myc,	 suggesting	
that	 Aurora-A	 must	 act	 through	 a	 kinase-independent	 mechanism.	 Certain	 Aurora-A	
inhibitors	 such	 as	 MLN8237/alisertib	 and	 CD532	 can	 destabilize	 N-Myc	 or	 c-Myc	 by	
disrupting	the	complex,	whilst	other	Aurora-A	inhibitors	have	little	effect	[42,	43,	44].		
	
Crystal	structure	of	the	Aurora-A/N-Myc	complex	
	
Aurora-A	 is	 best	 known	 for	 its	 role	 in	 the	 regulation	 of	 mitosis,	 specifically	 through	 the	
coordination	 of	 protein-protein	 interactions	 that	 govern	 the	 timing	 and	 robustness	 of	 the	
assembling	 mitotic	 spindle	 [45-48].	 The	 catalytic	 activity	 of	 Aurora-A	 is	 stimulated	 upon	
interaction	 with	 the	 microtubule-associated	 protein	 TPX2,	 which	 promotes	 kinase	
autophosphorylation	 [49,	 50].	 Crystal	 structures	 of	 Aurora-A	 show	 how	 this	 activation	
process	 converts	 the	 kinase	 from	 an	 inactive	 to	 an	 active	 conformation	 [51-53].	 Indeed,	
unlike	many	kinases	 that	are	 regulated	by	activation	 loop	phosphorylation,	 formation	of	a	
fully-active	 Aurora-A	 requires	 both	 phosphorylation	 and	 binding	 of	 TPX2	 [54].	 This	 is	
because	 the	 activation	 loop	 of	 Aurora-A	 is	 particularly	 dynamic,	 and	 requires	 both	 these	
events	to	 lock	 it	 into	a	conformation	that	 is	compatible	with	the	binding	of	substrates	[49,	
55,	56].	
	
We	recently	began	to	investigate	the	interaction	of	Aurora-A	with	N-Myc.	We	first	mapped	
the	regions	of	the	two	proteins	involved	in	the	interaction,	finding	that	the	catalytic	domain	
of	Aurora-A	interacts	directly	with	N-Myc	through	binding	sites	that	flank	either	side	of	MBI,	
a	region	spanning	residues	28-89	(Figure	1).	We	co-crystallized	this	fragment	of	N-Myc	with	
the	catalytic	domain	of	Aurora-A	phosphorylated	on	Thr288	and	determined	the	structure	of	
the	complex	[13].	There	was	clear,	unambiguous	electron	density	from	residues	61-89,	but	
unfortunately	 residues	 28-60	 were	 unresolved,	 perhaps	 due	 to	 competition	 with	 crystal	
packing	interactions.	N-Myc	residues	61-89	bind	to	the	interface	between	the	N-lobe	and	C-
lobe	of	 the	 kinase,	 interacting	with	 the	aC	helix,	 activation	 loop	and	aG	helix	 (Figure	2a).	
This	binding	site	is	different	from	the	location	of	TPX2	binding	or	the	expected	site	of	protein	
substrates,	 but	 there	 are	 overlaps	 (Figure	 2b,c).	 First	 of	 all,	 the	 pocket	 on	 the	 surface	 of	
Aurora-A	into	which	the	side	chain	of	N-Myc	Leu61	binds	is	also	recognized	by	the	side	chain	
of	 TPX2	 Trp30.	 	 Consistent	 with	 this	 structural	 overlap,	 N-Myc	 competes	 with	 TPX2	 for	
binding	 to	Aurora-A.	 Second,	 the	 side	 chain	 of	N-Myc	 Trp77	packs	 into	 the	 P+1	pocket	 of	
Aurora-A,	so	called	because	it	accommodates	the	side	chain	of	the	residue	one	position	after	
the	phosphorylated	Ser/Thr	of	kinase	substrates.	Based	on	this	observation,	we	thought	that	
N-Myc	might	block	kinase	activity	or	alter	the	substrate	specificity	of	Aurora-A.	 Indeed,	we	
found	 that	N-Myc	 competes	with	 substrate,	 but	 does	 not	 appear	 to	 change	 the	 substrate	
preference	of	the	kinase	(S.Burgess,	unpublished	data).		
	
	
Figure	2.	Proteins	binding	to	the	N-lobe/C-lobe	kinase	interface	in	three	different	binding	
modes.	 (a)	 Aurora-A	 (cyan)	 in	 complex	with	N-Myc	 residues	 61-89	 (red;	 PDB	 entry	 5G1X)	
[13].	 (b)	 Aurora-A	 (cyan)	 in	 complex	with	 TPX2	 residues	 7-43	 (magenta;	 PDB	 entry	 1OL5)	
[49].	 (c)	PKA	 (grey)	 in	complex	with	PRKACN1,	an	 inhibitory	substrate	analogue	 (blue;	PDB	
entry	1JBP)	 [57].	ADP	 is	 shown	as	white	 spheres.	 Phosphorylated	Thr288	 in	Aurora-A	and	
phosphorylated	Thr197	in	PKA	are	shown	as	yellow	spheres.	
	
Somewhat	 paradoxically,	 N-Myc	 dramatically	 enhances	 the	 activity	 of	 initially	
unphosphorylated	Aurora-A	by	stimulating	kinase	autophosphorylation.	Unfortunately,	our	
current	structure	of	the	complex	does	not	address	this	mechanism	because	residues	61-89	
of	 N-Myc	 are	 insufficient	 to	 activate	 the	 kinase.	 However,	 the	 crystal	 structure	 of	 the	
Aurora-A/N-Myc	complex	provides	some	insight	because	it	shows	the	kinase	in	a	fully	active	
conformation,	essentially	identical	to	that	observed	for	the	TPX2/Aurora-A	complex	(Figure	
2).	This	conformation	of	Aurora-A	is	necessary	for	the	formation	of	the	P+1	pocket,	to	which	
both	 the	 P+1	 residue	 of	 substrate	 polypeptides	 and	 Trp77	 of	 N-Myc	 bind.	 We	 therefore	
proposed	a	molecular	switch	mechanism	in	which	N-Myc	induces	Aurora-A	phosphorylation	
to	 form	 a	 stable	 scaffold	 on	 which	 a	 region	 of	 the	 N-Myc	 TAD	 folds.	 This	 stabilizes	 the	
conformation	of	N-Myc	and	alters	the	interactions	with	other	proteins	that	regulate	N-Myc	
stability,	and	may	potentially	contribute	to	the	regulation	of	N-Myc	function.	
	
The	 crystal	 structure	 of	 the	 Aurora-A/N-Myc	 complex	 clarifies	 the	 mechanism	 by	 which	
Aurora-A	inhibitors	such	as	alisertib	and	CD532	disrupt	the	interaction	with	Myc	[13].	These	
inhibitors	 promote	 structural	 changes	 in	 the	 kinase,	 twisting	 apart	 the	 two	 lobes	 of	 the	
kinase	and	distorting	the	conformation	of	the	activation	loop.	Thus,	in	the	presence	of	these	
inhibitors,	 the	binding	 site	 for	N-Myc	61-89	 is	disrupted.	The	 same	61-89	 region	of	N-Myc	
that	interacts	with	Aurora-A	in	the	crystal	structure	was	also	observed	to	form	a	low-affinity	
interaction	with	SCF
Fbxw7
.	We	proposed	 that	 if	 this	 interaction	were	 required	 for	 specifying	
K48-linked	ubiquitination	of	N-Myc,	perhaps	at	a	site	where	such	modification	is	crucial	for	
efficient	 degradation,	 then	 competition	with	Aurora-A	 for	 binding	 to	 this	 site	may	 explain	
the	 phenomena	 of	 Aurora-A-dependent	 stabilization	 of	 N-Myc	 and	 destabilization	 by	 the	
compounds	that	induce	Aurora-A	conformations	with	reduced	affinity	for	N-Myc.	
	
Figure	3.	Schematic	illustration	showing	the	antagonistic	binding	of	Myc	and	inhibitors	to	
Aurora-A.	 Aurora-A	 can	 adopt	 active	 and	 inactive	 conformations,	 characterized	 by	 the	
position	of	 the	N-lobe	and	activation	 loop.	N-Myc	and	c-Myc	bind	to	Aurora-A	 in	 its	active	
conformation,	 through	 overlapping	 but	 non-identical	 regions	 of	 the	Myc	 proteins.	 CD532	
and	 MLN8237	 bind	 to	 an	 inactive	 conformation	 of	 Aurora-A,	 which	 then	 blocks	 the	
formation	of	N-Myc	or	c-Myc	to	the	kinase.		CD532	displaces	N-Myc	from	Aurora-A,	and	so	
does	 MLN8237,	 albeit	 less	 efficiently	 (dashed	 arrow).	 In	 contrast,	 neither	 CD532	 nor	
MLN8237	can	displace	c-Myc	from	Aurora-A.	
	
Interactions	of	Aurora-A	with	c-Myc	and	L-Myc	
	
Aurora-A	 also	 stabilizes	 c-Myc	 in	 hepatocellular	 carcinoma	 (HCC)	 although	 it	 is	 unclear	
whether	 the	mechanism	 involves	disruption	of	 the	c-Myc/SCF
FbxW7
	 interaction	or	alteration	
of	c-Myc	ubiquitination	[44].	We	have	confirmed	direct	interactions	with	the	TADs	of	c-Myc	
and	L-Myc,	but	it	is	not	clear	how	these	proteins	interact	with	Aurora-A	because	the	region	
of	N-Myc	 spanning	 residues	61-89	 is	not	 conserved	 in	 c-Myc	or	 L-Myc.	 Indeed,	an	 in	 silico	
analysis	 by	 Zender	 and	 colleagues	 suggests	 that	 c-Myc	 binds	 to	 Aurora-A	 at	 a	 site	 that	
overlaps	 the	 location	 we	 discovered	 experimentally	 for	 N-Myc	 but	 predicts	 contributions	
from	 additional	 Myc	 residues	 to	 the	 interaction	 [44].	 However,	 these	 analyses	 await	
experimental	 verification.	 While	 we	 observed	 a	 direct	 interaction	 between	 purified,	
recombinant,	unphosphorylated	c-Myc	and	Aurora-A,	and	observed	no	effect	of	Thr58	and	
Ser62	 phosphorylation	 upon	 binding	 of	 N-Myc	 peptides	 to	 Aurora-A	 in	 vitro,	 Zender	 and	
colleagues	suggested	that	c-Myc	must	be	phosphorylated	on	Thr58	and	Ser62	to	efficiently	
bind	 Aurora-A	 [44].	 Since	 this	 was	 supported	 by	 an	 experiment	 in	 which	 a	 doubly	
phosphorylated	Myc	 46-89	 peptide	was	 incubated	with	 cell	 lysates,	 the	 observed	 binding	
may	have	 required	other	 cellular	 factors.	 For	example,	 there	may	be	another	protein	 that	
recognises	Thr58/Ser62	phosphorylated	Myc,	and	stabilizes	its	interaction	with	Aurora-A	in	a	
cellular	 context,	 but	 is	 dispensable	 for	 interaction	 in	 vitro	 or	 a	 protein	 that	 binds	 to	 the	
unphosphorylated	MBI,	blocking	 the	 interaction	with	Aurora-A	 in	cells,	and	 is	displaced	by	
MBI	phosphorylation,	revealing	the	binding	site.		
	Interestingly,	 CD532	 has	 an	 effect	 on	 N-Myc	 levels	 in	 neuroblastoma	 cells	 within	 hours,	
while	at	least	a	day	is	required	in	the	case	of	c-Myc	in	HCC	and	the	effects	of	MLN8237	are	
slow	 in	 both	 types	 of	 cancer	 cell	 [43,44].	 	 These	 differences	 suggest	 that	 c-Myc	 is	 more	
effective	 than	 N-Myc	 in	 locking	 Aurora-A	 in	 a	 conformation	 that	 cannot	 be	 reversed	 by	
inhibitors	 (Figure	 3).	 However,	 these	 differences	 may	 also	 reflect	 the	 distinct	 biological	
contexts	of	the	two	tumour	types	in	which	the	complexes	were	studied.	Further	studies	are	
required	 to	 elucidate	 the	 structural	 basis	 of	 c-Myc/Aurora-A	 interactions,	 the	 role	 of	Myc	
phosphorylation	 in	 complex	 formation,	and	 the	mechanisms	 that	underpin	 the	differential	
effects	of	 inhibitors	 in	cells	derived	from	neuroblastoma,	HCC	and	other	cancer	types.	The	
differential	 activity	 between	 CD532	 and	 MLN8237	 might	 be	 due	 to	 differences	 in	 their	
binding	to	Aurora-A	(CD532	induces	a	more	pronounced	twist	between	the	N-	and	C-lobes)	
or	due	 to	differences	 in	off-target	 inhibition	of	other	 kinases.	 These	 issues	 require	 further	
study	but	both	MLN8237	and	CD532	are,	nevertheless,	valuable	chemical	tools	for	the	study	
of	the	Aurora-A/Myc	interaction.		
	
Conclusion	
	
Myc	 proteins	 consist	 of	 a	 series	 of	 conserved	 sequence	 motifs	 in	 the	 context	 of	 an	
intrinsically	 disordered	 protein	 that	 adopt	 ordered	 conformations	 only	 in	 presence	 of	
binding	 partners.	 These	 binding	 partners	 have	 roles	 associated	 with	 transcriptional	
regulation,	 chromatin-modification,	 stability	 and	 in	many	 cases	are	 likely	 to	be	 required	
for	the	oncogenic	functions	of	Myc.	Inhibiting	these	interactions	with	ligands	that	stabilize	
Myc	in	its	disordered	form	are	becoming	possible	and	now	structures	of	small,	conserved	
Myc	 fragments	 in	 complex	 with	 their	 binding	 partners	 are	 being	 resolved	 using	 NMR	
spectroscopy	 or	 X-ray	 crystallography	 and	 are	 providing	 new	 insights	 into	Myc	 biology.	
The	Myc	proteins	are	of	huge	importance	as	cancer	drug	targets,	yet	their	lack	of	ordered	
domains	has	deprived	us	of	pockets	 that	 could	be	 targeted	 in	drug	discovery	 initiatives.	
Structures	such	as	these,	which	reveal	the	ordered	conformations	that	sub-regions	of	Myc	
can	 adopt	when	 in	 complex	with	 other	 proteins,	may	 allow	 us	 to	 bring	 structure-based	
drug	design	to	bear	on	Myc	after	all.	
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